miR-150 is a negative independent prognostic biomarker for primary gastrointestinal diffuse large B-cell lymphoma
Autor: | Lihua Qiu, Lanfang Li, Peng Ge, Yutian Kan, Zhengzi Qian, Xiaofang Wang, Zhigang Zhao, Xinyuan Wang, Leiyuan Chen, Yong Yu, Haifeng Zhao, Yafei Wang, Hongliang Yang, Xianming Liu, Qiongli Zhai, Huilai Zhang, Tingting Ding |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty PGI-DLBCL 03 medical and health sciences 0302 clinical medicine International Prognostic Index miR-150 Internal medicine hemic and lymphatic diseases Medicine Stage (cooking) miRNA Receiver operating characteristic business.industry Area under the curve Cancer Articles medicine.disease Lymphoma 030104 developmental biology 030220 oncology & carcinogenesis Biomarker (medicine) biomarker prognosis business Diffuse large B-cell lymphoma |
Zdroj: | Oncology Letters |
ISSN: | 1792-1082 1792-1074 |
Popis: | A number of studies suggest an association between miRNAs and diffuse large B-cell lymphoma (DLBCL). The present study aimed to investigate the prognostic value of microRNA (miR-150) in primary gastrointestinal (PGI)-DLBCL, by assessing the association between miR-150 expression and clinicopathological characteristics in patients with PGI-DLBCL. A total of 84 patients diagnosed with PGI-DLBCL were recruited and both tumor and adjacent non-tumor tissue samples were collected. miR-150 expression was assessed via reverse transcription-quantitative (RT-q)PCR analysis. The results demonstrated that miR-150 expression was significantly lower in PGI-DLBCL tissues compared with adjacent non-tumor tissues. Furthermore, receiver operating characteristic (ROC) curve analysis indicated that the optimal cut-off value of miR-150 for predicting survival was 8.965 with high sensitivity (79.8%) and specificity (77.1%). Patients were divided into two groups according to this cut-off value, as follows: High (n=18) and low expression (n=66) groups. Low miR-150 expression was significantly associated with clinical stage, International Prognostic Index (IPI), Eastern Cooperative Oncology Group status and use of rituximab. RT-qPCR analysis demonstrated that miR-150 expression was significantly lower in patients with high IPI scores compared with patients with low IPI scores. Downregulated miR-150 expression was significantly associated with shorter overall survival (OS) time and progression-free survival (PFS) time in patients with PGI-DLBCL. Furthermore, miR-150 level and IPI score were identified as two risk factors for OS and PFS. The diagnostic value of miR-150 was evaluated via ROC curve analysis, with an area under the curve value of 0.882. Taken together, the results of the present study suggest that miR-150 is a potential diagnostic marker of PGI-DLBCL, and may also serve as a useful prognostic factor for survival outcomes in patients with PGI-DLBCL. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |